Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTH1R | Q03431 | 2/20 | 0.54 |
| ▸ | TFPI | P10646 | 1/20 | 0.54 |
| ▸ | VIPR1 | P32241 | 2/20 | 0.53 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.52 |
| ▸ | VIPR2 | P41587 | 2/20 | 0.52 |
| ▸ | ECE1 | P42892 | 1/20 | 0.51 |
| ▸ | GLP1R | P43220 | 1/20 | 0.51 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30198769 | 0.93 | TFPI (0.65) | PTH1RTFPIVIPR1VIPR2 | |
| SCHEMBL30571155 | 0.91 | BACE1 (0.54) | PTH1RVIPR1KISS1RVIPR2 | |
| SCHEMBL20764456 | 0.90 | TFPI (0.57) | TFPI | |
| SCHEMBL30974237 | 0.90 | TFPI (0.58) | PTH1RTFPIVIPR1VIPR2ECE1 | |
| SCHEMBL30974318 | 0.90 | TFPI (0.58) | PTH1RTFPIVIPR1VIPR2ECE1 | |
| SCHEMBL30974343 | 0.90 | TFPI (0.58) | PTH1RTFPIVIPR1VIPR2ECE1 | |
| SCHEMBL30512795 | 0.89 | KISS1R (0.62) | PTH1RTFPIVIPR1KISS1RVIPR2 | |
| SCHEMBL30974472 | 0.89 | TFPI (0.58) | PTH1RTFPIVIPR1KISS1RVIPR2 | |
| SCHEMBL29679607 | 0.89 | TFPI (0.56) | TFPIVIPR1KISS1RVIPR2ECE1 | |
| SCHEMBL30974327 | 0.89 | TFPI (0.53) | PTH1RTFPIVIPR1VIPR2ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122005750-A | Application of bombyx mori neuropeptide BommoOKA _type4 in preparation of anti-melanoma medicine | 广西壮族自治区蚕业技术推广站(广西壮族自治区蚕种质量检验检疫站、广西壮族自治区蚕业科学研究院) | 2026-05-12 | — | — | CN | disclosed |
| US-12613247-B2 | Labelling method to distinguish isobaric amino acids and amino acid combinations | RAPID NOVOR INC. (CA) | 2026-04-28 | — | — | US | disclosed |
| CN-121248746-A | Brown planthopper myophilic neuropeptide orcokinin-A and application thereof | 扬州大学 | 2026-01-02 | — | — | CN | disclosed |
| CN-121248746-A | Brown planthopper myophilic neuropeptide orcokinin-A and application thereof | 扬州大学 | 2026-01-02 | — | — | CN | disclosed |
| US-20250388544-A1 | HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES | VIVORYON THERAPEUTICS N.V. (DE) | 2025-12-25 | — | — | US | disclosed |
| US-12378186-B2 | Inhibitors of meprin α and β | VIVORYON THERAPEUTICS N.V. (DE) | 2025-08-05 | — | — | US | disclosed |
| EP-3750878-B1 | HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES | VIVORYON THERAPEUTICS N V (DE) | 2025-05-14 | — | — | EP | disclosed |
| EP-3967679-B1 | NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA | VIVORYON THERAPEUTICS AG (DE) | 2025-02-19 | — | — | EP | disclosed |
| CN-114507175-B | Novel inhibitors of hypnotins alpha and beta | 维沃里翁治疗股份有限公司 | 2024-10-01 | — | — | CN | disclosed |
| EP-3899532-B1 | A LABELLING METHOD TO DISTINGUISH ISOBARIC AMINO ACIDS AND AMINO ACID COMBINATIONS | RAPID NOVOR INC (CA) | 2024-02-14 | — | — | EP | disclosed |
| US-20230122243-A1 | Heteroaromatic inhibitors of astacin proteinases | VIVORYON THERAPEUTICS N.V. (DE) | 2023-04-20 | — | — | US | disclosed |
| CN-114585608-A | Heteroaromatic inhibitors of astacin protease | 维沃永治疗公众有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-114507175-A | Novel inhibitors of hypnotic proteins alpha and beta | 维沃里翁治疗股份有限公司 | 2022-05-17 | — | — | CN | disclosed |
| EP-3986868-A1 | HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES | Vivoryon Therapeutics N.V. (DE) | 2022-04-27 | — | — | EP | disclosed |
| EP-3967679-A1 | NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA | Vivoryon Therapeutics AG (DE) | 2022-03-16 | — | — | EP | disclosed |
| CN-109195947-B | Novel inhibitors of hypnotic proteins alpha and beta | 维沃里翁治疗股份有限公司 | 2022-03-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230122243-A1 | Heteroaromatic inhibitors of astacin proteinases | BMP1, DPEP1, MEP1A | PTH1R 709/4885TFPI 799/4885VIPR1 2017/4885 |
| US-20250388544-A1 | HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES | BMP1, BMPR1A, BMPR1B | PTH1R 1055/4885TFPI 1496/4885VIPR1 1801/4885 |
| US-12613247-B2 | Labelling method to distinguish isobaric amino acids and amino acid combinations | DNPEP, ASNS, ANPEP | PTH1R 1634/4885TFPI 2335/4885VIPR1 705/4885 |
| US-12378186-B2 | Inhibitors of meprin α and β | MEP1A, MEP1B, CAPRIN1 | PTH1R 2407/4885TFPI 236/4885VIPR1 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.